Athira Pharma to Present Phase 2/3 LIFT-AD Trial Results at CTAD 2024; Shares Up 17%
    Athira Pharma to Present Phase 2/3 LIFT-AD Trial Results at CTAD 2024; Shares Up 17%
    PRISM Biotech

    October 22, 2024 - by Alex Corbit

    Athira Pharma to Present Phase 2/3 LIFT-AD Trial Results at CTAD 2024; Shares Up 17%

    22 October 2024

    New York, October 22, 2024 - PRISM MarketView - Athira Pharma, Inc. (Nasdaq: ATHA), a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, announced that it will present the results of its Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 conference in Madrid. The presentation will take place on October 29, 2024.

    Athira Pharma, Inc. - Prism MarketView

    At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer’s, Parkinson’s disease dementia, and dement

    Read More

    The LIFT-AD trial did not meet the primary endpoint for statistical significance but showed favorable trends in cognition and function in certain subgroups of patients with moderate Alzheimer’s disease and APOE4 carriers. Biomarker data related to neurodegeneration and inflammation also showed positive trends consistent with fosgonimeton’s neuroprotective mechanism.

    “We believe the totality of the data supports the potential of HGF modulation for the treatment of neurodegenerative diseases.” 

    Javier San Martin, M.D., Chief Medical Officer of Athira

    Athira’s shares are currently trading up 17% on the news.
    The company continues to advance its pipeline, including the next-generation small molecule ATH-1105, currently in a Phase 1 trial as a potential treatment for ALS and Alzheimer’s disease, with further developments expected by year-end.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    To see this content properly accept cookies.
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.